Mr. Haddadin rejoined our board of directors in April 2018 after previously serving from October 2017 to March 2018. Mr. Haddadin joined GMS Holdings in 2017 to build and lead the company’s investment management platform, GMS Capital Partners LLC. He has over 20 years of investment banking and private equity experience. Throughout his career, he has developed extensive experience across a range of industries and advised on over USD 100 billion in M&A transactions in North America, Latin America, Europe, the Middle East and Africa.
Prior to joining GMS Holdings, Mr. Haddadin was the Chief Executive Officer and Board Member of a regional investment bank based in Amman and Dubai (2014-2017); Advisor at Ripplewood Holdings LLC, a New York-based private equity firm (2013-2014); Managing Director at Perella Weinberg Partners in New York (2007-2013) and an Executive Director in JPMorgan’s M&A Group in New York (2000-2007).
Mr. Haddadin is a Fellow of the sixth class of the Middle East Leadership Initiative and a member of the Aspen Global Leadership Network. Previously, he was a member of the Board of Directors at Sixth of October Investment Company (SODIC), a publicly listed Egyptian real estate development company and a Board Member of The Near East Foundation, a New York- based private nonprofit development agency with projects in Africa and the Middle East.
Mr. Haddadin holds a Juris Doctor from Northwestern University School of Law (USA) and a Bachelor of Science from Georgetown’s School of Foreign Service (USA). He is admitted to the New York State Bar Association and is an FAA licensed pilot.
What is Yezan Munther Haddadin's net worth?
The estimated net worth of Yezan Munther Haddadin is at least $26,658.72 as of March 28th, 2024. Mr. Haddadin owns 5,049 shares of Outlook Therapeutics stock worth more than $26,659 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Haddadin may own. Learn More about Yezan Munther Haddadin's net worth.
How do I contact Yezan Munther Haddadin?
Has Yezan Munther Haddadin been buying or selling shares of Outlook Therapeutics?
Yezan Munther Haddadin has not been actively trading shares of Outlook Therapeutics during the last ninety days. Most recently, on Thursday, March 28th, Yezan Munther Haddadin bought 1,882 shares of Outlook Therapeutics stock. The stock was acquired at an average cost of $11.82 per share, with a total value of $22,245.24. Following the completion of the transaction, the director now directly owns 5,049 shares of the company's stock, valued at $59,679.18. Learn More on Yezan Munther Haddadin's trading history.
Who are Outlook Therapeutics' active insiders?
Are insiders buying or selling shares of Outlook Therapeutics?
In the last year, Outlook Therapeutics insiders bought shares 2 times. They purchased a total of 6,882 shares worth more than $50,695.24. The most recent insider tranaction occured on September, 26th when CFO Lawrence A Kenyon bought 5,000 shares worth more than $28,450.00. Insiders at Outlook Therapeutics own 3.4% of the company.
Learn More about insider trades at Outlook Therapeutics. Information on this page was last updated on 9/26/2024.
